Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis

New England Journal of Medicine

Volumn 337, Issue 6, 1997, Pages 382-387

  Adachi, Jonathan D ^a,k   Bensen, William G ^a   Brown, Jacques ^b   Hanley, David ^c   Hodsman, Anthony ^d   Josse, Robert ^e   Kendler, David L ^f   Lentle, Brian ^f   Olszynski, Wojciech ^g   Ste Marie, Louis George ^h   Tenenhouse, Alan ⁱ   Chines, Arkadi A ^j   Jovaisas, Algis ^l   Sturtridge, William C ^e   Anastassiades, Tassos P ^m   Hanly, John G ⁿ   Pope, Janet E ^d   Dias, Reginald ^o   Horowitz, Zebulun D ^o   Pack, Simon ^o  

^a ST JOSEPH S HOSPITAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g UNIVERSITY OF SASKATCHEWAN   (Canada)

^h UNIVERSITY OF MONTREAL   (Canada)

ⁱ MONTREAL GENERAL HOSPITAL   (Canada)

^j PROCTER AND GAMBLE COMPANY   (United States)

^k University of Ottawa ^*  (Canada)

^l UNIVERSITY OF OTTAWA   (Canada)

^m QUEEN S UNIVERSITY   (Canada)

ⁿ DALHOUSIE UNIVERSITY   (Canada)

^o PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; ETIDRONIC ACID; PLACEBO;

ADULT; AGED; ARTICLE; BONE ATROPHY; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE SEVERITY; FEMALE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTEBRA FRACTURE;

EID: 0030752221     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199708073370603     Document Type: Article

References (18)

1. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990;112:352-64.
2. Dempster DW, Arlot MA, Meunier PJ. Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis. Calcif Tissue Int 1983;35:410-7
3. Suzuki Y, Ichikawa Y, Saito E, Homma M. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism 1983;32: 151-6.
4. Ruegsegger P, Medici TC, Anliker M. Corticosteroid-induced bone loss: a longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography. Eur J Clin Pharmacol 1983;25:615-20.
5. Gennari C, Civitelli R, Agnusdei D. Corticosteroid-induced osteoporosis. In: Christiansen C, Overgaard K, eds. Osteoporosis. Copenhagen, Denmark: Osteopress ApS, 1990:1529-38.
6. Mulder H, Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol 1994;33:348-50.
7. Adachi JD, Cranney A, Goldsmith CH, et al. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss. J Rheumatol 1994;21:1922-6.
8. Miller TD, Hamilos DL, McIntyre DO, et al. Cyclical etidronate (CE) increases bone mass in patients with established steroid-induced osteoporosis (SlOP). J Bone Miner Res 1993;8:Suppl 2:S338. abstract.
9. Fogelman I, Smith L, Mazess R, Wilson MA, Bevan JA. Absorption of oral diphosphonate in normal subjects. Clin Endocrinol (Oxf) 1986;24: 57-62.
10. Ritchie DM, Boyle JA, McInnes JM, et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 1968;37:393-406.
11. van Kuijk C, Genant HK. Radiological aspects. In: Riggs BL, Melton LJ III, eds. Osteoporosis: etiology, diagnosis, and management. 2nd ed. Philadelphia: Lippincott-Raven, 1995:249-73.
12. Mulder H, Snelder HAA. Effect of cyclical etidronate regimen on prophylaxis of bone loss of glucocorticoid (prednisone) therapy in postmenopausal women. Bone Miner 1992;7:Suppl 1:S331. abstract.
13. Diamond T, McGuigan L, Barbagallo S, Bryant C. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induccd bone loss in postmenopausal women. Am J Med 1995;98:459-63.
14. Sebaldt RJ, Adachi JD, Bensen WG, et al. Intermittent cyclic therapy with etidronate prevents eorticosteroid-induced bone loss: two years of follow-up. Scand J Rheumatol Suppl 1996;103:91-3.
15. Sambrook P, Birmingham J, Kelly P, et al. Prevention of corticosteroid osteoporosis: a comparison of calcium, calcitriol, and calcitonin. N Engl J Med 1993;328:1747-52.
16. Healey JH, Paget SA, Williams-Russo P, et al. A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica. Calcif Tissue Int 1996;58:73-80.
17. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994;79:1693-700.
18. Chesnut CH III, Bell NH, Clark GS, et al. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 1997;102:29-37.